- Home
- TAC vs PTCT Comparison
TAC vs PTCT Comparison
Compare TAC & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TAC
- PTCT
- Stock Information
- Founded
- TAC 1909
- PTCT 1998
- Country
- TAC Canada
- PTCT United States
- Employees
- TAC N/A
- PTCT N/A
- Industry
- TAC Electric Utilities: Central
- PTCT Biotechnology: Pharmaceutical Preparations
- Sector
- TAC Utilities
- PTCT Health Care
- Exchange
- TAC Nasdaq
- PTCT Nasdaq
- Market Cap
- TAC 5.1B
- PTCT 5.3B
- IPO Year
- TAC N/A
- PTCT 2013
- Fundamental
- Price
- TAC $14.71
- PTCT $75.70
- Analyst Decision
- TAC Strong Buy
- PTCT Buy
- Analyst Count
- TAC 4
- PTCT 17
- Target Price
- TAC $21.63
- PTCT $73.24
- AVG Volume (30 Days)
- TAC 2.3M
- PTCT 1.1M
- Earning Date
- TAC 11-06-2025
- PTCT 11-04-2025
- Dividend Yield
- TAC 1.23%
- PTCT N/A
- EPS Growth
- TAC N/A
- PTCT N/A
- EPS
- TAC N/A
- PTCT 8.94
- Revenue
- TAC $1,783,342,546.00
- PTCT $1,779,150,000.00
- Revenue This Year
- TAC N/A
- PTCT $119.02
- Revenue Next Year
- TAC N/A
- PTCT N/A
- P/E Ratio
- TAC N/A
- PTCT $8.42
- Revenue Growth
- TAC N/A
- PTCT 97.54
- 52 Week Low
- TAC $7.82
- PTCT $35.95
- 52 Week High
- TAC $17.88
- PTCT $76.80
- Technical
- Relative Strength Index (RSI)
- TAC 39.30
- PTCT 79.67
- Support Level
- TAC $13.52
- PTCT $69.23
- Resistance Level
- TAC $15.98
- PTCT $73.98
- Average True Range (ATR)
- TAC 0.74
- PTCT 2.67
- MACD
- TAC -0.39
- PTCT 0.40
- Stochastic Oscillator
- TAC 26.52
- PTCT 89.08
About TAC TransAlta Corporation
TransAlta Corp is an independent power producer based in Alberta, Canada. The company operates a diverse and growing fleet of electrical power generation assets in Canada, the United States, and Australia. The company has six reportable segments namely, Hydro, Wind & Solar, Energy Marketing, Gas, Energy Transition segment and Corporate Segment. The company generates the majority of its revenue from the gas segment.
About PTCT PTC Therapeutics Inc.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.